Teplizumab in relatives at risk for type 1 diabetes. [Carta] (2019)
- Authors:
- USP affiliated authors: FARIAS, KELEN CRISTINA RIBEIRO MALMEGRIM DE - FCFRP ; RODRIGUES, MARIA CAROLINA DE OLIVEIRA - FMRP
- Unidades: FCFRP; FMRP
- DOI: 10.1056/NEJMc1912500
- Subjects: DIABETES MELLITUS; ANTICORPOS; LINFÓCITOS T; INSULINA
- Language: Inglês
- Imprenta:
- Source:
- Título: New England Journal of Medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 381, n. 19, p. 1879-1881, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
COURI, Carlos Eduardo Barra e FARIAS, Kelen Cristina Ribeiro Malmegrim de e OLIVEIRA, Maria Carolina. Teplizumab in relatives at risk for type 1 diabetes. [Carta]. New England Journal of Medicine. Waltham: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1056/NEJMc1912500. Acesso em: 28 dez. 2025. , 2019 -
APA
Couri, C. E. B., Farias, K. C. R. M. de, & Oliveira, M. C. (2019). Teplizumab in relatives at risk for type 1 diabetes. [Carta]. New England Journal of Medicine. Waltham: Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo. doi:10.1056/NEJMc1912500 -
NLM
Couri CEB, Farias KCRM de, Oliveira MC. Teplizumab in relatives at risk for type 1 diabetes. [Carta] [Internet]. New England Journal of Medicine. 2019 ; 381( 19): 1879-1881.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1056/NEJMc1912500 -
Vancouver
Couri CEB, Farias KCRM de, Oliveira MC. Teplizumab in relatives at risk for type 1 diabetes. [Carta] [Internet]. New England Journal of Medicine. 2019 ; 381( 19): 1879-1881.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1056/NEJMc1912500 - New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
- Editorial: immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
- Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: where do we stand?
- Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy
- Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
- Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II
- Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers
- New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
- CMV-specific clones may lead to reduced TCR diversity and relapse in systemic sclerosis patients treated with AHSCT [Carta]
- Thymus rejuvenation after autologous hematopoietic stem cell transplantation in patients with autoimmune diseases
Informações sobre o DOI: 10.1056/NEJMc1912500 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003009702.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
